Last reviewed · How we verify

Panitumumab plus GEMOX chemotherapy

Prof. Massimo Aglietta · Phase 2 active Small molecule

Panitumumab plus GEMOX chemotherapy is a Small molecule drug developed by Prof. Massimo Aglietta. It is currently in Phase 2 development. Also known as: panitumumab: Vectibix, Gemcitabine, Oxaliplatin.

At a glance

Generic namePanitumumab plus GEMOX chemotherapy
Also known aspanitumumab: Vectibix, Gemcitabine, Oxaliplatin
SponsorProf. Massimo Aglietta
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Panitumumab plus GEMOX chemotherapy

What is Panitumumab plus GEMOX chemotherapy?

Panitumumab plus GEMOX chemotherapy is a Small molecule drug developed by Prof. Massimo Aglietta.

Who makes Panitumumab plus GEMOX chemotherapy?

Panitumumab plus GEMOX chemotherapy is developed by Prof. Massimo Aglietta (see full Prof. Massimo Aglietta pipeline at /company/prof-massimo-aglietta).

Is Panitumumab plus GEMOX chemotherapy also known as anything else?

Panitumumab plus GEMOX chemotherapy is also known as panitumumab: Vectibix, Gemcitabine, Oxaliplatin.

What development phase is Panitumumab plus GEMOX chemotherapy in?

Panitumumab plus GEMOX chemotherapy is in Phase 2.

Related